A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.

Key facts

Study ID

NCT00566397

Run by

Pfizer

People needed

402

Starts

2007-12-01

Expected to finish

2010-12-01

Last updated by the study team

2018-11-30

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening.
• Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization

You may not qualify if…

• Current evidence or history of neurological, psychiatric and any other illness that could contribute to non-Alzheimer's dementia.
• Known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations.
• Evidence or history of diabetes mellitus Type 1 or Type 2.
• History or symptoms of autoimmune disorders.

Where it is running

• Pfizer Investigational Site — Sun City, Arizona, United States
• Pfizer Investigational Site — Irvine, California, United States
• Pfizer Investigational Site — Irvine, California, United States
• Pfizer Investigational Site — Irvine, California, United States
• Pfizer Investigational Site — Irvine, California, United States
• Pfizer Investigational Site — La Jolla, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Martinez, California, United States
• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Orange, California, United States
• Pfizer Investigational Site — Palo Alto, California, United States
• Pfizer Investigational Site — Sacramento, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — Vista, California, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — Washington D.C., District of Columbia, United States
• Pfizer Investigational Site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.